intralesional steroid
ApprovedSmall molecule
intralesional steroid is one of 54 small molecule programs targeting Oral Submucous Fibrosis. It is currently in Approved.
3
Indications
4
Total Trials
2
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
113 competitors in Alopecia Areata
#DrugCompanyPhaseTrials
1Opzelura
PfizerPhase 3
Olumiant
Eli LillyPhase 3
Rinvoq
AbbViePhase 3
PF-06651600
PfizerPhase 3
Orencia
Bristol-Myers SquibbPhase 2
intralesional steroid
KKasr El Aini Hospital
Approved
Jaktinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Cosentyx
NovartisPhase 2
Jakafi
IncytePhase 2
Velsipity
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Alopecia Areata2 trials
Paronychia1 trial
Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial.
Active, not recruiting·—·Phase 3·NCT07311759·21 enrolled
Oral Submucous Fibrosis1 trial
Comparison of Curcumin and Intralesional Steroids in Oral Submucous Fibrosis
Not yet recruiting·SServices Institute of Medical Sciences, Pakistan·Phase 3·NCT06758739·70 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for intralesional steroid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- KKasr El Aini Hospital